New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:38 EDTPPHMPeregrine receives FDA fast track designation for Bavituximab
Peregrine Pharmaceuticals announced that the company has received Fast Track designation by the FDA for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer, or NSCLC. Recently, the company initiated SUNRISE, a pivotal Phase III clinical trial comparing bavituximab plus the chemotherapy docetaxel against placebo plus docetaxel in this indication.
News For PPHM From The Last 14 Days
Check below for free stories on PPHM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PPHM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use